Loading
Life sciences · Journal article
Current Oncology · August 18, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a single-patient case report of a 60-year-old man with de novo metastatic prostate adenocarcinoma (Gleason 9) who received standard androgen deprivation therapy and concurrently adopted a whole-food, low-fat vegan diet, structured exercise, and periodic fasting-mimicking cycles. PSA declined from 808.3 µg/L to 1.7 µg/L over 14 months with concurrent improvements in body composition and metabolic biomarkers; however, the design does not permit attribution of benefit to lifestyle intervention independent of standard therapy.
Single-patient case report. A 60-year-old, physically active male, lifelong non-smoker without significant comorbidities, diagnosed with de novo metastatic prostate adenocarcinoma (Gleason score 9).. Intervention: Whole-food, low-fat vegan diet, structured physical activity, and periodic fasting-mimicking diet cycles, concurrent with standard androgen deprivation therapy.. n = 1.
PSA declined from 808.3 µg/L to 1.7 µg/L (>99.8% reduction) over 14-month follow-up period. PSA remained suppressed throughout the 14-month follow-up period. Concurrent improvements observed in body composition and metabolic biomarkers.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This case suggests that integrative oncology approaches combining standard therapy with lifestyle modifications are feasible and may be associated with favorable PSA response; however, clinicians cannot infer that lifestyle intervention independently improved outcomes. Controlled studies are needed before any practice guidance can be offered.
A single-patient case report with no control group; while the clinical outcome is favorable, the design cannot isolate the effect of lifestyle intervention from standard therapy, and the source explicitly states findings are hypothesis-generating.
As stated by the source record.
Quoted from the source exactly as published.
This case suggests that integrative oncology approaches combining standard therapy with lifestyle modifications are feasible and may be associated with favorable PSA response; however, clinicians cannot infer that lifestyle intervention independently improved outcomes. Controlled studies are needed before any practice guidance can be offered.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Prostate cancer is among the most frequently diagnosed cancers in men globally, with metastatic disease contributing substantially to morbidity and mortality. While conventional therapies remain the standard of care, dietary and lifestyle behaviors are increasingly explored as potentially modifiable factors influencing clinical outcomes, although their role in advanced disease is not well established. We report a 60-year-old, physically active male, lifelong non-smoker without significant comorbidities, diagnosed with de novo metastatic prostate adenocarcinoma (Gleason score 9) and an initial prostate-specific antigen (PSA) of 808.3 µg/L. The patient received standard androgen deprivation therapy. By personal choice, he adopted a whole-food, low-fat (WFLF) vegan diet, structured physical activity, and periodic fasting-mimicking diet cycles. These interventions complemented, but did not replace or delay, conventional treatment. During the 14-month follow-up period, serial PSA measurements, laboratory tests, blood pressure monitoring, dietary assessment, body composition analysis, imaging, and germline genetic testing were performed. PSA declined from 808.3 µg/L to 1.7 µg/L (>99.8%), and remained suppressed throughout follow-up. Concurrent improvements were observed in body composition and metabolic biomarkers. The WFLF vegan diet increased fiber and micronutrient intake while reducing saturated fat and cholesterol. This case demonstrates the successful application and execution of an integrative oncology approach and highlights metastatic prostate cancer managed with standard therapy alongside patient-initiated lifestyle modifications. The findings should be interpreted as descriptive, exploratory, and hypothesis-generating. Given the single-patient design, the independent impact of lifestyle interventions cannot be determined. Controlled studies are warranted to clarify their potential role in advanced prostate cancer management.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.